Epitalon

Epitalon (also known as Epithalon or Epithalone) is a synthetic tetrapeptide, meaning it is a chain of four amino acids—alanine, glutamic acid, aspartic acid, and glycine.

Key Benefits

• May support healthy aging and cellular longevity processes
• Commonly researched for promoting better sleep quality and circadian rhythm regulation
• May help support antioxidant defenses and cellular repair mechanisms
• Research suggests potential benefits for immune function, recovery, and overall wellness support

FDA-Approved Uses

Conditions studied in research

• Anti-aging / longevity (primary research focus — Khavinson Institute, Russia)
• Insomnia / circadian rhythm normalization (under PCAC review)
• Telomere elongation (in vitro and animal; no confirmed human data)
• Age-related retinal degeneration
• Melatonin restoration in aging
• Cancer prevention / tumor incidence reduction (animal models)
• Immune senescence reversal

Trade Names in USA and Manufacturers

Also known as:
– Epithalon / Epithalone (alternative spellings)
– AEDG (amino acid abbreviation: Ala-Glu-Asp-Gly)
– Pineal tetrapeptide

Discovery:

• Developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Russia (1980s)
• Synthetic analogue of Epithalamin — a polypeptide complex from bovine pineal gland tissue
• Primary research institution: St. Petersburg Institute of Bioregulation and Gerontology (Khavinson group)

US availability (as of May 2026):

• Grey-market research peptide vendors: Widely available (‘research use only’)
• 503A compounding: Pending formal PCAC July 2026 review outcome
• Some US telehealth longevity clinics have begun offering it in anticipation of Category 1 formalization — verify current legal status

Molecular identity:

• Synthetic tetrapeptide (4 amino acids): Ala-Glu-Asp-Gly
• One of the smallest known bioactive peptides
• MW: ~390 Daltons
• Chemical formula: C₁₄H₂₂N₄O₉
• Readily soluble in water and saline

Dosage

KEY PRINCIPLE: Cyclical low-dose protocol — NOT continuous daily use.
Short cycles are sufficient to trigger downstream effects on telomerase and melatonin.

Subcutaneous injection (most studied route):
Dose: 5–10 mg per injection
Frequency: Once daily
Cycle: 10–20 consecutive days
Rest period: 3–6 months before next cycle
Annual use: 1–3 cycles per year
Typical: 10 mg SC daily × 10–14 days → 3–6 months off

Intramuscular injection:
Same dose range: 5–10 mg IM daily × 10 days

Oral / sublingual:
Higher doses needed: 20–100 mg/day (unestablished bioavailability)
Cyclical use still recommended
SC injection is the evidence-supported route

Reconstitution:
Lyophilized powder (5 mg, 10 mg vials)
Reconstitute with 1–2 mL Bacteriostatic Water
Store lyophilized at -18°C or below
Reconstituted: refrigerate; use within 14–21 days
Relatively stable vs. larger peptides due to small size

Pricing

No FDA-approved commercial pricing.

Research peptide vendors (unregulated):
5 mg vial: ~$20–$40
10 mg vial: ~$30–$60
Per cycle (10 mg/day × 10 days): ~$60–$150

US telehealth longevity clinics:
~$200–$600/cycle including physician consultation

Post-Category 1 (pending July 2026):
Compounded from licensed 503A: ~$150–$400/cycle
[HealingMaps 2026: ‘$150–$400 per treatment cycle at compounding pharmacies’]

Annual cost (2–3 cycles/year):
Grey-market: ~$120–$450/year
Compounded: ~$300–$1,200/year

Among the more affordable longevity peptides due to small MW (simple synthesis) and cyclical (not daily) use.

Tips

• Monitor July 24, 2026 PCAC outcome — FDA evaluating Epitalon specifically for INSOMNIA. Submit public comments to FDA docket FDA-2025-N-6895 by July 9, 2026 if you have relevant clinical data.
• PCAC is reviewing for INSOMNIA — not anti-aging or telomere extension. The evidence base for sleep/insomnia is more clinically measurable and tangible than longevity claims.
• TELOMERASE / CANCER RISK: Telomerase is overexpressed in ~85–90% of all human cancers. Compounds that activate telomerase theoretically could promote cancer cell immortality. Anyone with active malignancy, cancer history, or strong family cancer history should not use Epitalon until this is addressed in long-term human oncology safety studies.
• WADA: Not prohibited — athletes can use without anti-doping risk.
• The majority of clinical data comes from ONE research group (Khavinson, St. Petersburg). Independent Western replication is very limited — flagged in the 2025 systematic review as a significant limitation.
• Short cycles (10–14 days) with long rest periods (3–6 months) are the consistent protocol from source research. Do not use daily continuously.
• Request CoA with HPLC purity ≥98%.

Side Effects

Generally favorable safety profile — but comprehensive human data is critically limited.

Best available human study:
– 2002 trial (Khavinson; n=162 patients): No serious adverse events in Epitalon group

Commonly reported:
– Injection site reactions: Mild redness, swelling, pain (most common)
– Fatigue or mild drowsiness
– Headache (mild, transient)
– Nausea (mild, uncommon)
– Vivid dreams (melatonin modulation)
– Hormonal shifts: Melatonin and cortisol changes; generally not clinically significant at standard doses

FDA-stated concerns (prior Category 2 basis):
– Immunogenicity: Theoretical immune reaction risk; no confirmed clinical cases published
– Insufficient comprehensive safety data — FDA’s concern reflects absence of data rather than confirmed harm

2025 systematic review (Araj et al., IJMS):
– ‘Information regarding critical issues about this peptide’s safety is missing’
– Called for comprehensive human clinical trials before any therapeutic recommendation

CRITICAL UNRESOLVED CONCERN — CANCER RISK FROM TELOMERASE ACTIVATION:
Telomerase is overexpressed in ~85–90% of all human cancers enabling cellular immortality. No confirmed human cancer cases from Epitalon published, but this risk has not been resolved by long-term human oncology safety studies.

Contraindications

No formal FDA contraindications (no approved label).

Strong caution / avoid:
– Active malignancy or significant cancer history/risk: Telomerase activation — most serious unresolved concern; avoid until long-term human oncology safety data exists
– Pregnancy and breastfeeding: No safety data; unpredictable implications; not recommended

Use with caution:
– Children and adolescents: Telomerase modulation in developing cells is unpredictable
– Autoimmune conditions: Immunomodulatory effects may interact with disease activity
– Hypothyroidism or hyperthyroidism: Neuroendocrine regulation may interact with thyroid axis
– Patients on melatonin supplements or sleep medications: Possible additive effects
– Hypersensitivity to Epitalon or components

International note: Canada and Australia prohibit Epitalon for human sale — reflecting their evidence-to-risk balance assessment.

Pharmacology

Epitalon (Ala-Glu-Asp-Gly; AEDG) is a synthetic tetrapeptide (4 amino acids) — one of the smallest known biologically active peptides. Developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Russia, as a synthetic analogue of naturally occurring bioregulator peptides from bovine pineal gland extracts (Epithalamin).

Molecular details:
– Sequence: Ala-Glu-Asp-Gly
– MW: ~390 Daltons — exceptionally small
– Chemical formula: C₁₄H₂₂N₄O₉
– Readily soluble in water and saline

Classification: ‘Bioregulator peptide’ — short peptides designed to regulate gene expression and restore normal tissue function via chromatin-modifying mechanisms.

Physiological context:
– Derived from pineal gland — the neuroendocrine organ responsible for melatonin synthesis and circadian rhythm regulation
– Pineal gland undergoes calcification and functional decline with aging → melatonin production decreases
– Epitalon proposed to restore pineal function, normalizing melatonin secretion and circadian signaling

Stability: Relatively stable vs. larger peptides due to small MW; cold-chain storage still recommended.

Mechanism of action

Epitalon exerts effects through several interconnected mechanisms:

1. Telomerase Activation — hTERT Upregulation (primary mechanism):
Upregulates hTERT (human telomerase reverse transcriptase) in cell culture and some animal studies
→ Theoretically elongates shortened telomeres → delays cellular senescence → extends replicative lifespan
DUAL-EDGE: Same telomerase activation enables cancer cell immortality
Telomerase is overexpressed in ~85–90% of all human cancers

2. Melatonin Restoration and Circadian Rhythm Normalization:
Stimulates pineal gland to restore age-related melatonin decline
→ Normalizes circadian rhythm disruption
→ Improves sleep architecture (basis for PCAC insomnia review)
→ Melatonin has independent antioxidant and immune-regulatory functions

3. Antioxidant and Cytoprotective Effects:
→ Reduces reactive oxygen species (ROS)
→ Upregulates superoxide dismutase (SOD) and catalase
→ Reduces oxidative DNA damage (antimutagenic)

4. Chromatin Remodeling / Gene Expression Regulation:
Per Khavinson’s bioregulator theory:
→ Interacts directly with chromatin (DNA-histone complex)
→ Normalizes gene expression patterns that drift with aging
→ Proposed to ‘reset’ epigenetic age-related changes

5. Immunomodulation:
→ Normalizes age-related immune senescence
→ Restores T-cell function in aging
→ Balances cytokine profiles

6. Neuroendocrine Regulation:
→ Normalizes hypothalamic-pituitary axis dysfunction occurring with aging

Result Claims By Different Companies

Prof. Khavinson / St. Petersburg Institute (primary research group):

Longevity / lifespan extension (animal models):
– Fruit fly studies: Mean lifespan extended up to 11–13%
– Rat studies: Lifespan extension ~11–16%
– Cancer-prone rat strains: Reduced spontaneous tumor incidence

Telomere elongation (in vitro):
– Human fetal fibroblasts: Telomere elongation and increased replicative lifespan reported (Khavinson et al., 2003)
– No confirmed in vivo human telomere data from controlled clinical trials

Human sleep / insomnia:
– Normalized melatonin circadian rhythm in elderly patients with melatonin deficiency
– Improvement in sleep onset and sleep quality — basis for PCAC insomnia review

2002 Clinical trial (n=162): No serious adverse events

2025 Systematic Review (Araj et al., IJMS):
– ‘Significant geroprotective and neuroendocrine effects’ acknowledged
– ‘Information regarding critical issues about this peptide’s safety is missing’
– Called for comprehensive human clinical trials

2015 ADDF Cognitive Vitality Report:
– ‘No severe adverse events’ in multi-year epithalamin trials in older adults
– Evidence insufficient for clinical recommendation; called for independent Western validation

KEY LIMITATIONS:
1. Majority of studies from ONE research group (Khavinson)
2. Mostly Russian-language publications — limited Western peer review
3. No large-scale independent blinded RCTs in Western journals
4. Human telomere elongation not confirmed in controlled trials
5. Cancer risk from telomerase activation unresolved
6. PCAC reviewing for INSOMNIA only — not anti-aging or telomere claims

Disclaimer

This content about “Epitalon (Epithalon / Epithalone / AEDG) Pineal Tetrapeptide Bioregulator” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.